By Assoc. Prof. Dr. Mehmet Sorar | Published: 11.02.2025
TMS Treatment: The Internal Dynamics of Magnetic Stimulation
A protocol for transcranial magnetic stimulation (TMS) is more than one machine setting. It is defined by the brain region stimulated, how often pulses are delivered, how many pulses are given, the type of coil and the number and timing of sessions. These settings differ between conditions and between devices. Detailed claims about how the pulses change the brain deserve caution.
Which settings define a TMS protocol?
The main settings are the target region, pulse frequency, number of pulses, number of sessions, and the coil and pulse shape. A 2023 meta-analysis by Vida and colleagues shows how far they vary even within one condition. It pooled trials of add-on high-frequency, left-sided repetitive TMS (rTMS) for depression that had not improved after at least two antidepressants (19 trials with 854 patients for response). Across those trials:
- Pulse frequency ranged from 5 to 20 hertz (pulses per second).
- Courses ranged from 10 to 30 sessions.
- The total pulses ranged from 6,000 to 120,000.
These ranges measure how much trials differ. They are not recommendations. The Oxford Health NHS Foundation Trust leaflet (2026) gives one concrete example for depression. Its accelerated intermittent theta-burst protocol uses sessions of 1,800 pulses over 9 minutes, three sessions a day with a 50 minute gap, for 10 days, which makes 30 sessions. Its standard course is one session a day for about 6 weeks, each lasting about 30 minutes. The 2021 IFCN guideline by Rossi and colleagues was updated to cover newer devices and pulse shapes.
Does the target region depend on the condition?
Yes. The 2020 European guideline by Lefaucheur and colleagues grades evidence for a particular stimulation in a particular condition, not for TMS in general. Level A means definite efficacy and Level B probable efficacy. Both rest on differences between real and sham (fake) stimulation that were repeated across enough independent studies.
| Condition | Stimulation named in the guideline | Level |
|---|---|---|
| Depression | High-frequency stimulation of the left dorsolateral prefrontal cortex | A |
| Neuropathic pain | High-frequency stimulation of the motor cortex opposite the painful side | A |
| Hand recovery after stroke (after the acute stage) | Low-frequency stimulation of the motor cortex on the opposite side | A |
| Parkinson's disease (motor impairment or depression) | High-frequency stimulation of the motor cortex on both sides, or of the left prefrontal cortex | B |
| Lower-limb spasticity in multiple sclerosis | Intermittent theta burst | B |
The motor cortex directs movement and the prefrontal cortex lies at the front of the brain. The Oxford service also stimulates the left prefrontal cortex for depression. The table shows that evidence for one protocol does not transfer to another condition. Alzheimer's disease and the Parkinson Plus conditions are not on the guideline's Level A or B lists. The guideline covers literature to the end of 2018, so it is more than five years old, and its authors caution that a benefit supported by statistics does not automatically reach clinical relevance.
Does the same target give the same results in every condition?
No. A 2023 analysis in Lancet Psychiatry by Kan and colleagues pooled sham-controlled trials of left prefrontal rTMS across neuropsychiatric disorders (174 studies, 7,905 patients). The largest effects were on craving (Hedges g, a measure of effect size, of -0.80) and depressive symptoms (g of -0.73). Effects were small but significant, with g of about -0.2 to -0.5, for anxiety, obsessions or compulsions, pain, global cognition, memory, cognitive control and motor coordination.
There was no significant effect on attention, suicidal thoughts, language, walking ability, fatigue or sleep. Differences between the trials were large for the two biggest effects. The abstract does not list which diagnoses were combined, and pooling across diagnoses limits how far the figures apply to any one condition.
How do standard, theta-burst and deep TMS differ?
Standard repetitive TMS is given in longer sessions and theta-burst in much shorter ones. In the Oxford leaflet a standard session lasts about 30 minutes and a theta-burst session 9 minutes. Deep TMS is a form that reaches broader and deeper brain regions. A 2024 systematic review by Di Passa and colleagues covered 28 sham-controlled deep TMS trials. Support for efficacy was most consistent in obsessive-compulsive disorder (OCD, only 2 trials), substance use disorders (8 trials) and depressive episodes in major depression or bipolar disorder (6 trials). Results were mixed for attention deficit hyperactivity disorder, post-traumatic stress disorder and schizophrenia and limited or mixed for other conditions.
A coil type or protocol name alone therefore does not signal effectiveness. Which forms have regulatory clearance for which condition is set out on the page about what TMS is and what has been cleared.
What do the settings change about safety, and what is known about how TMS works?
Settings can affect seizure risk. The Oxford leaflet says the risk may be higher with its accelerated protocol. The IFCN guideline says the risk is low with traditional parameters and focal coils, even in people taking drugs that act on the central nervous system. Those two statements describe different protocols. If a seizure happens away from the clinic, call emergency services. Numbers and exclusions are on the page about TMS side effects and safety data.
On mechanism, the guidance and reviews cited here do not set out which neural processes are involved or how long any change lasts, so phrases such as "rebuilds connections" or "reprograms the brain" are not established. Effect size is also sensitive to trial design. Vida and colleagues found a smaller effect than earlier meta-analyses and linked this to stricter inclusion criteria and better blinding, which means participants were less able to tell which stimulation they received.
What can you ask about a protocol?
Asking for the settings is the most concrete way to judge both the evidence and the risk. You can ask:
- Which region will be stimulated, and which evidence level does that choice have for your condition?
- What is the pulse frequency, the number of pulses per session and the session length?
- Is the programme standard, theta-burst or accelerated? If accelerated, what does that mean for seizure risk?
- How and when will your response be measured? Vida and colleagues defined response as at least a 50% fall in the symptom score.
- In which patients were the studies behind this protocol done?
More questions for a centre are in the guide to choosing a TMS doctor in Ankara.
Sources
- Vida et al.: Efficacy of repetitive transcranial magnetic stimulation (rTMS) adjunctive therapy for major depressive disorder (MDD) after two antidepressant treatment failures, BMC Psychiatry 2023
- Lefaucheur et al.: Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014-2018), Clinical Neurophysiology 2020
- Kan et al.: Effects of repetitive transcranial magnetic stimulation of the left dorsolateral prefrontal cortex on symptom domains in neuropsychiatric disorders, Lancet Psychiatry 2023
- Oxford Health NHS Foundation Trust: rTMS patient information leaflet (v7.0, 2026)
- Rossi et al.: Safety and recommendations for TMS use in healthy subjects and patient populations (IFCN expert guidelines), Clinical Neurophysiology 2021
- Di Passa et al.: Clinical efficacy of deep transcranial magnetic stimulation (dTMS) in psychiatric and cognitive disorders: A systematic review, Journal of Psychiatric Research 2024
This article is for general information and does not replace medical diagnosis or treatment. Please consult your physician for advice about your own condition.
Assoc. Prof. Dr. Mehmet Sorar
Neurosurgeon in Ankara. Graduated from Gazi University Faculty of Medicine in 1997, specialist since 2004, associate professor since 2019. Full CV
Related treatment page: TMS Tedavisi